Literature DB >> 32595428

Validation of Spiked Postmortem Blood Samples from Cornea Donors on the Abbott ARCHITECT and m2000 Systems for Viral Infections.

Ingo Schmack1,2, Seda Ballikaya1, Brigitte Erber1, Irina Voehringer1, Ulrich Burkhardt3,4, Gerd U Auffarth1, Paul Schnitzler4.   

Abstract

BACKGROUND: Transplantation of human corneal tissue is associated with the potential risk of transmittance of viral infections. In accordance with European directives and federal laws, in Germany each tissue donor has to be tested for infectious diseases such as hepatitis B and C virus (HBV and HCV) and human immunodeficiency virus (HIV) infection. However, most of the currently available CE-marked serologic and nucleic acid screening systems are only validated for antemortem blood.
METHODS: Twenty related and paired ante- and postmortem blood samples from cornea donors were obtained and subsequently analyzed for hepatitis B surface antigen (HBsAg), hepatitis B antibody (anti-HBc), anti-HCV, HCV RNA, anti-HIV-1/2, and HIV p24 Ag using Abbott test systems. The sera were also spiked with reference materials in concentrations giving low and high positivity for HBV, HCV, and HIV markers.
RESULTS: The spiked ante- and postmortem sera from related donors showed similar results for HBsAg, anti-HBc, anti-HCV, HCV RNA, anti-HIV, and HIV p24 Ag, indicating a high stability of viral markers in cadaveric specimens. Three cornea donors had a medical history of HBV infection and revealed anti-HBc at similar levels in the ante- and postmortem sera. In addition, there was a single postmortem sample demonstrating a weak signal of anti-HIV-1 and HIV-1 p24 Ag. False-positive or false-negative results were not detected. The results obtained with the Abbott ARCHITECT analyzer and Abbott RealTime HCV PCR showed no significant differences.
CONCLUSION: The analyzed screening assays are suitable for the detection of infectious markers of HBV, HCV, and HIV at similar levels in spiked ante- and postmortem sera from cornea donors.
Copyright © 2019 by S. Karger AG, Basel.

Entities:  

Keywords:  Cornea donor; Hepatitis B virus; Hepatitis C virus; Human immunodeficiency virus; Postmortem blood samples; Serologic screening

Year:  2019        PMID: 32595428      PMCID: PMC7315216          DOI: 10.1159/000502866

Source DB:  PubMed          Journal:  Transfus Med Hemother        ISSN: 1660-3796            Impact factor:   3.747


  27 in total

1.  Qualification of serological infectious disease assays for the screening of samples from deceased tissue donors.

Authors:  A D Kitchen; J A Newham
Journal:  Cell Tissue Bank       Date:  2010-04-18       Impact factor: 1.522

2.  Validation of Virus NAT for HIV, HCV, HBV and HAV Using Post-Mortal Blood Samples.

Authors:  Knut Gubbe; Yvonne Scharnagl; Steffi Grosch; Torsten Tonn; Michael Schmidt; Kai M Hourfar; Andreas Karl; Erhard Seifried; Ina Wilkemeyer; Ulrich Kalus
Journal:  Transfus Med Hemother       Date:  2012-11-13       Impact factor: 3.747

3.  Serological viral testing of cadaveric cornea donors.

Authors:  Dominique Challine; Françoise Roudot-Thoraval; Patrick Sabatier; Fabienne Dubernet; Patrick Larderie; Pierrette Rigot; Jean-Michel Pawlotsky
Journal:  Transplantation       Date:  2006-09-27       Impact factor: 4.939

4.  Eine erfolgreiche totale Keratoplastik (A successful total keratoplasty). 1906.

Authors:  E K Zirm
Journal:  Refract Corneal Surg       Date:  1989 Jul-Aug

5.  NAT for HBV and anti-HBc testing increase blood safety.

Authors:  W Kurt Roth; Marijke Weber; Detlev Petersen; Christian Drosten; Sylvia Buhr; Walid Sireis; Wolfgang Weichert; Doris Hedges; Erhard Seifried
Journal:  Transfusion       Date:  2002-07       Impact factor: 3.157

6.  Screening of blood from potential organ and cornea donors for viruses.

Authors:  Marcel Miédougé; Martine Chatelut; Jean-Michel Mansuy; Lionel Rostaing; François Malecaze; Karine Sandres-Sauné; Francis Boudet; Jacqueline Puel; Michel Abbal; Jacques Izopet
Journal:  J Med Virol       Date:  2002-04       Impact factor: 2.327

7.  A prospective time-course study on serological testing for human immunodeficiency virus, hepatitis B virus and hepatitis C virus with blood samples taken up to 48 h after death.

Authors:  Carolin Edler; Birgit Wulff; Ann-Sophie Schröder; Ina Wilkemeyer; Susanne Polywka; Thomas Meyer; Ulrich Kalus; Axel Pruss
Journal:  J Med Microbiol       Date:  2011-03-24       Impact factor: 2.472

8.  Infectious disease screening of blood specimens collected post-mortem provides comparable results to pre-mortem specimens.

Authors:  Cristina Baleriola; Harpreet Johal; Peter Robertson; Brendan Jacka; Ross Whybin; Peter Taylor; William D Rawlinson
Journal:  Cell Tissue Bank       Date:  2011-04-08       Impact factor: 1.522

9.  Validation of Serological Testing for Anti-Treponema pallidum from Postmortem Blood on the Siemens-BEP(®)-III Automatic System.

Authors:  Ulrich Kalus; Ina Wilkemeyer; Axel Pruss; Gregor Caspari
Journal:  Transfus Med Hemother       Date:  2013-10-17       Impact factor: 3.747

Review 10.  Infectious disease transmission through cell, tissue, and organ transplantation: reducing the risk through donor selection.

Authors:  T Eastlund
Journal:  Cell Transplant       Date:  1995 Sep-Oct       Impact factor: 4.139

View more
  1 in total

1.  Algorithms for the Testing of Tissue Donors for Human Immunodeficiency Virus, Hepatitis B Virus, and Hepatitis C Virus.

Authors:  Axel Pruß; Akila Chandrasekar; Jacinto Sánchez-Ibáñez; Sophie Lucas-Samuel; Ulrich Kalus; Holger F Rabenau
Journal:  Transfus Med Hemother       Date:  2020-12-22       Impact factor: 3.747

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.